… clinical trials in HF, both of which randomized participants to treatment with dapagliflozin
or placebo and which were pooled for analysis across the range of left ventricular ejection …

… heart failure with reduced ejection fraction (HFrEF). The cardiovascular (CV) benefits of
dapagliflozin were first observed in the DECLARE-TIMI 58 trial, in which dapagliflozin 10 mg/day …

… receiving optimal guideline-directed medical therapy and provide further evidence for
dapagliflozin as a new treatment option for HFrEF. Interestingly, despite the different mortality and …

… dapagliflozin on the incidence of ventricular arrhythmias and sudden death in patients with
heart failure … DAPA-HF was a randomized, double-blind, controlled trial in patients with HFrEF…

… -CKD trial broaden the utility of dapagliflozin as a therapeutic option in patients with advanced
kidney disease… the existing evidence on dapagliflozin in heart failure with reduced ejection …

… Using a pooled analysis from 2 randomized trials of patients with HF, we demonstrate that
SGLT2 inhibitor dapagliflozin produced significant and clinically meaningful improvements in …

… patients randomized to dapagliflozin 10 mg or placebo with a history of HF were pooled from
five clinical trials. … -controlled trials was to assess the efficacy and safety of dapagliflozin 10 …

… Therefore, in the light of the results of the DELIVER trial, in which the benefits of dapagliflozin
were seen irrespective of baseline NT-proBNP concentrations [11,31], our data strongly …

… of 2 trials comparing dapagliflozin to placebo in patients with … we provide a detailed report
of the effects of dapagliflozin on … , in Black compared with White patients across the range of …

… Failure) trial enrolled 4744 patients with HF and reduced ejection fraction (EF) who … of
dapagliflozin (a SGLT2 inhibitor) or placebo. The DAPA-HF trial clearly showed that dapagliflozin …